Stock Events

Bionano Genomics 

$0.55
990
-$0.02-3.91% Friday 20:00

Statistics

Day High
0.58
Day Low
0.52
52W High
6.76
52W Low
0.52
Volume
3,114,955
Avg. Volume
1,425,795
Mkt Cap
36.68M
P/E Ratio
-0.1
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.24
-0.86
-0.49
-0.11
Expected EPS
-0.64
Actual EPS
-0.6

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BNGO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacific Biosciences of California
PACB
Mkt Cap373.13M
Pacific Biosciences offers long-read sequencing technologies that compete with Bionano's optical genome mapping solutions for complex genetic research and diagnostics.
Illumina
ILMN
Mkt Cap16.63B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics market space that Bionano targets.
Thermo Fisher Scientific
TMO
Mkt Cap211.09B
Thermo Fisher Scientific offers a broad range of instruments and reagents for genomic research, including next-generation sequencing, competing with Bionano's genomic analysis technologies.
Agenus
AGEN
Mkt Cap351.74M
Agilent Technologies provides instruments, software, services, and consumables for the entire laboratory workflow, including genomics research, competing with Bionano's offerings.
Qiagen NV
QGEN
Mkt Cap9.38B
Qiagen offers sample to insight solutions, including next-generation sequencing and molecular diagnostics that compete with Bionano's genomic analysis solutions.
Intellia Therapeutics
NTLA
Mkt Cap2.16B
Intellia Therapeutics is involved in CRISPR/Cas9 technology for genome editing, which competes indirectly with Bionano's genomic mapping and analysis technologies by offering alternative approaches to genetic research and diagnostics.
Editas Medicine
EDIT
Mkt Cap384.05M
Editas Medicine operates in the genome editing space using CRISPR technology, offering a competitive alternative to Bionano's genomic analysis and mapping solutions.
CRISPR Therapeutics
CRSP
Mkt Cap4.59B
CRISPR Therapeutics is focused on developing gene-based medicines using CRISPR/Cas9 technologies, indirectly competing with Bionano's genomic analysis tools by providing alternative methods for genetic research.
Twist Bioscience
TWST
Mkt Cap2.87B
Twist Bioscience operates in the synthetic biology and genomics field, producing synthetic DNA that is used in genetic research, competing with Bionano's genomic analysis and mapping technologies.

Analyst Ratings

4$Average Price Target
The highest estimate is $6.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Professional, Scientific, and Technical Services
Testing Laboratories
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Show more...
CEO
R. Erik Holmlin
Employees
344
Country
US
ISIN
US09075F1075
WKN
000A2JRLZ

Listings